Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects

Sándor Somodi, I. Seres, Hajnalka Lorincz, M. Harangi, Péter Fülöp, György Paragh

Research output: Contribution to journalArticle

Abstract

Background. The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals. Subjects and Methods. We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results. The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction. Conclusion. The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.

Original languageEnglish
Article number9596054
JournalInternational Journal of Endocrinology
Volume2018
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Plasminogen Activator Inhibitor 1
Lipoproteins
Aryldialkylphosphatase
IDL Lipoproteins
HDL Lipoproteins
Lipid Metabolism
Peroxidase
Interleukin-6
Tumor Necrosis Factor-alpha
Spectrophotometry
Waist Circumference
Type 2 Diabetes Mellitus
Healthy Volunteers
Obesity
Enzyme-Linked Immunosorbent Assay
Regression Analysis

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems

Cite this

Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects. / Somodi, Sándor; Seres, I.; Lorincz, Hajnalka; Harangi, M.; Fülöp, Péter; Paragh, György.

In: International Journal of Endocrinology, Vol. 2018, 9596054, 01.01.2018.

Research output: Contribution to journalArticle

@article{7ffc888b11ea4535bac53283851a344a,
title = "Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects",
abstract = "Background. The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals. Subjects and Methods. We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results. The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction. Conclusion. The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.",
author = "S{\'a}ndor Somodi and I. Seres and Hajnalka Lorincz and M. Harangi and P{\'e}ter F{\"u}l{\"o}p and Gy{\"o}rgy Paragh",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/9596054",
language = "English",
volume = "2018",
journal = "International Journal of Endocrinology",
issn = "1687-8337",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Plasminogen activator inhibitor-1 level correlates with lipoprotein subfractions in obese nondiabetic subjects

AU - Somodi, Sándor

AU - Seres, I.

AU - Lorincz, Hajnalka

AU - Harangi, M.

AU - Fülöp, Péter

AU - Paragh, György

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background. The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals. Subjects and Methods. We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results. The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction. Conclusion. The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.

AB - Background. The elevated level of plasminogen activator inhibitor-1 (PAI-1) in obese subjects with metabolic syndrome and in patients with type 2 diabetes is well established. The association of plasma PAI-1 and lipid metabolism is still unclear. The aim of the present study was to determine the relationship between plasma PAI-1 levels and the distribution of lipoprotein subfractions in obese and lean nondiabetic individuals. Subjects and Methods. We enrolled fifty nondiabetic obese patients and thirty-two healthy volunteers. Lipoprotein subfractions were detected with Lipoprint System. Plasma PAI-1, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO) concentrations were determined with enzyme-linked immunosorbent assay (ELISA), while serum paraoxonase-1 (PON1) activities were measured by spectrophotometry. Results. The TNF-α, IL-6, oxidized low-density lipoprotein (oxLDL), and MPO levels were found to be significantly higher, while PON1 paraoxonase and arylesterase activities were nonsignificantly lower in the obese patients. Strong significant negative correlations were found between plasma PAI-1 concentration and mean LDL size, as well as between PAI-1 concentrations and the levels of the large and intermediate high-density lipoprotein (HDL) subfractions. In multiple regression analysis, PAI-1 was predicted by waist circumference and intermediate HDL subfraction. Conclusion. The significant correlations between PAI-1 levels and lipoprotein subfractions indicate the link between PAI-1 and lipid metabolism in obesity.

UR - http://www.scopus.com/inward/record.url?scp=85055668438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055668438&partnerID=8YFLogxK

U2 - 10.1155/2018/9596054

DO - 10.1155/2018/9596054

M3 - Article

AN - SCOPUS:85055668438

VL - 2018

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

SN - 1687-8337

M1 - 9596054

ER -